Lifirafenib
- Generic Name
- Lifirafenib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H17F3N4O3
- CAS Number
- 1446090-79-4
- Unique Ingredient Identifier
- 8762XZS5ZF
- Background
Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).
- Associated Conditions
- -
- Associated Therapies
- -
SpringWorks Therapeutics Reports Third Quarter 2024
SpringWorks Therapeutics reports $49.3 million in OGSIVEO® (nirogacestat) net product revenue in Q3, with long-term Phase 3 DeFi trial data showing tumor size reduction and consistent safety. The FDA granted Priority Review for mirdametinib's NDA, and SpringWorks has $498 million in cash to fund operations through anticipated profitability in H1 2026.
SpringWorks Therapeutics, Inc. SEC 10-Q Report
SpringWorks Therapeutics reported $49.3M revenue for Q3 2024, driven by OGSIVEO sales, with a net loss of $53.5M. The company launched OGSIVEO in 2023, expanded dosage strengths in 2024, and seeks EMA approval for Europe in 2025. Mirdametinib for NF1-PN is under FDA priority review. SpringWorks plans to invest in R&D and expand OGSIVEO globally, despite facing regulatory, operational, and financial risks.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath